Evidence mapPaperPMID 38558708Full record

ReviewCureus2024

Navigating the Gut-Cardiac Axis: Understanding Cardiovascular Complications in Inflammatory Bowel Disease.

Tanya Sinha, Zukhruf Zain, Syed Faqeer Hussain Bokhari, Sarosh Waheed, Taufiqa Reza, Anthony Eze-Odurukwe, Mitwa Patel, Mohammed Khaleel I Kh Almadhoun, Azlaan Hussain, Ibrahim Reyaz

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 6 countries.

Tanya SinhaMedical Education, Tribhuvan University, Kirtipur, NPL.
Zukhruf ZainFamily Medicine, Aga Khan University Hospital, Karachi, PAK.
Syed Faqeer Hussain BokhariSurgery, King Edward Medical University, Lahore, PAK.
Sarosh WaheedMedicine, Gujranwala Medical College, Gujranwala, PAK.
Taufiqa RezaMedicine, Avalon University School of Medicine, Youngstown, USA.
Anthony Eze-OdurukweSurgery, Salford Royal NHS Foundation Trust, Manchester, GBR.
Mitwa PatelMedicine, David Tvildiani Medical University, Tbilisi, GEO.
Mohammed Khaleel I Kh AlmadhounMedicine and Surgery, Mutah University, Karak, JOR.
Azlaan HussainMedicine and Surgery, Mayo Hospital, Lahore, PAK.
Ibrahim ReyazInternal Medicine, Christian Medical College and Hospital, Ludhiana, IND.
Christian Medical College & Hospital · INKing Edward Medical University · PKMutah University · JOAga Khan University Hospital · PKSalford Royal NHS Foundation Trust · GBTribhuvan University · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) presents a complex interplay of chronic inflammation in the gastrointestinal tract and is associated with various extraintestinal manifestations, including cardiovascular complications (CVCs). IBD patients face an elevated risk of CVCs, including coronary artery disease, heart failure, arrhythmias, stroke, peripheral artery disease, venous thromboembolism, and mesenteric ischemia, necessitating comprehensive cardiovascular risk assessment and management. The intricate interplay between chronic inflammation, genetic predisposition, environmental factors, and immune dysregulation likely contributes to the development of CVCs in IBD patients. While the exact mechanisms linking IBD and CVCs remain speculative, potential pathways may involve shared inflammatory pathways, endothelial dysfunction, dysbiosis of the gut microbiome, and traditional cardiovascular risk factors exacerbated by the chronic inflammatory state. Moreover, IBD medications, particularly corticosteroids, may impact cardiovascular health by inducing hypertension, insulin resistance, and dyslipidemia, further amplifying the overall CVC risk. Lifestyle factors such as smoking, obesity, and dietary habits may also exacerbate cardiovascular risks in individuals with IBD. Lifestyle modifications, including smoking cessation, adoption of a heart-healthy diet, regular exercise, and optimization of traditional cardiovascular risk factors, play a fundamental role in mitigating CVC risk. Emerging preventive strategies targeting inflammation modulation and gut microbiome interventions hold promise for future interventions, although further research is warranted to elucidate their efficacy and safety profiles in the context of IBD. Continued interdisciplinary collaboration, advanced research methodologies, and innovative interventions are essential to address the growing burden of CVCs in individuals living with IBD and to improve their long-term cardiovascular outcomes.

Indexed as

arrhythmiascardiovascular complicationscoronary artery diseaseheart failureibdinflammatory bowel diseasemesenteric ischemiaperipheral artery diseasestrokevenous thromboembolism

Identifiers

PMID38558708
PMCPMC10981543
OpenAlexW4392299319

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.